Q4 2024 EPS Estimates for Hims & Hers Health, Inc. Reduced by Analyst (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) - Stock analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for Hims & Hers Health in a report issued on Tuesday, May 7th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $0.03 per share for the quarter, down from their prior forecast of $0.04. Leerink Partnrs currently has a "Market Perform" rating on the stock. The consensus estimate for Hims & Hers Health's current full-year earnings is $0.11 per share.

Other equities analysts have also issued reports about the company. SVB Leerink began coverage on Hims & Hers Health in a research note on Monday, February 26th. They issued a "market perform" rating and a $10.00 price objective on the stock. Canaccord Genuity Group began coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They issued a "buy" rating and a $20.00 price objective on the stock. Piper Sandler lifted their price objective on Hims & Hers Health from $11.00 to $13.00 and gave the stock a "neutral" rating in a research note on Tuesday. Canaccord Genuity Group began coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They issued a "buy" rating and a $20.00 price objective on the stock. Finally, Imperial Capital upgraded Hims & Hers Health from an "in-line" rating to an "outperform" rating and set a $16.00 price objective on the stock in a research note on Wednesday, February 28th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $15.08.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock traded down $0.63 during trading on Friday, reaching $12.29. The company's stock had a trading volume of 6,990,293 shares, compared to its average volume of 5,241,197. The business's fifty day moving average price is $13.99 and its 200-day moving average price is $10.42. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of -117.45 and a beta of 0.97. Hims & Hers Health has a one year low of $5.65 and a one year high of $17.16.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The company had revenue of $278.20 million during the quarter, compared to analysts' expectations of $270.37 million. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. The business's quarterly revenue was up 45.8% compared to the same quarter last year.

Insider Activity

In other news, CEO Andrew Dudum sold 188,888 shares of the company's stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total value of $2,827,653.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, insider Soleil Boughton sold 2,503 shares of the business's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $15.65, for a total value of $39,171.95. Following the transaction, the insider now directly owns 166,866 shares of the company's stock, valued at approximately $2,611,452.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the business's stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total value of $2,827,653.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 723,602 shares of company stock worth $9,607,432. Company insiders own 31.63% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Graham Capital Management L.P. boosted its holdings in shares of Hims & Hers Health by 39.4% in the 3rd quarter. Graham Capital Management L.P. now owns 340,338 shares of the company's stock worth $2,141,000 after acquiring an additional 96,277 shares in the last quarter. Swiss National Bank boosted its holdings in shares of Hims & Hers Health by 9.2% in the 3rd quarter. Swiss National Bank now owns 309,200 shares of the company's stock worth $1,945,000 after acquiring an additional 26,100 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company's stock worth $88,857,000 after acquiring an additional 428,671 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Hims & Hers Health by 11.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company's stock worth $3,551,000 after acquiring an additional 58,288 shares in the last quarter. Finally, Must Asset Management Inc. acquired a new position in shares of Hims & Hers Health in the 3rd quarter worth approximately $1,596,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.